中国动物传染病学报
中國動物傳染病學報
중국동물전염병학보
CHINESE JOURNAL OF VETERINARY PARASITOLOGY
2012年
5期
45-49
,共5页
赵其平%李婷%韩红玉%舒凡帆%朱顺海%姜连连%孔春林%王晔%薛璞%黄兵%董辉
趙其平%李婷%韓紅玉%舒凡帆%硃順海%薑連連%孔春林%王曄%薛璞%黃兵%董輝
조기평%리정%한홍옥%서범범%주순해%강련련%공춘림%왕엽%설박%황병%동휘
柔嫩艾美耳球虫%早熟株%疫苗%免疫
柔嫩艾美耳毬蟲%早熟株%疫苗%免疫
유눈애미이구충%조숙주%역묘%면역
Eimeria tenella%precocious line%vaccine%immunization
为了确定柔嫩艾美耳球虫（Eimenatenella）早熟株合适的免疫剂量，本文设立7个早熟株免疫攻虫组、1个不免疫攻虫组和1个不免疫不攻虫组，免疫组的免疫剂量为孢子化卵囊100、200、400、600、800、1000和2000个／羽，经嗉囊感染，7日龄首次免疫，14日龄以同等剂量进行第二次免疫，21日龄以8×10^4个／羽的同源母株进行攻虫，28日龄结束试验，以存活率、增重、肠道病变记分、血便数量、卵囊减少率为观测指标。对免疫保护效果较好的3个免疫剂量进行重复试验，同时设置商品化球虫疫苗对照组，免疫方法、试验周期、试验指标同第一批试验。结果显示：攻虫后，不免疫攻虫组出现5％死亡，而各免疫组来出现死亡；各免疫组卵囊减少率在61．57％～69．52％；200～2000免疫组的增重与不免疫不攻虫组差异不具备显著统计学意义（P〉0．05）；600～2000免疫组的肠道病变记分和血便数量均明显少于不免疫攻虫组（P〈0．05）。用600、800和1000进行重复试验，三个免疫组攻虫期间均来出现死亡，而不免疫组和疫苗对照组均出现5％死亡；三个免疫组的增重均明显高于不免疫攻虫组和疫苗对照组（P〈0．05）；早熟株免疫组的肠道病变记分和血便数量明显低于不免疫攻虫组（P〈0．05），而疫苗对照组与不免疫攻虫组的相当（P〉0．05）；卵囊减少率在66.30％-78．75％，高于疫苗对照组的51．82％。结果表明，该柔嫩艾美耳球虫早熟株保持了良好的免疫原性，不同免疫剂量均能诱发鸡产生免疫保护力，其中600、800和1000个／羽的免疫效果均优于疫苗对照组，可考虑以600个／羽作为该早熟株在疫苗制备中的推荐免疫剂量。
為瞭確定柔嫩艾美耳毬蟲（Eimenatenella）早熟株閤適的免疫劑量，本文設立7箇早熟株免疫攻蟲組、1箇不免疫攻蟲組和1箇不免疫不攻蟲組，免疫組的免疫劑量為孢子化卵囊100、200、400、600、800、1000和2000箇／羽，經嗉囊感染，7日齡首次免疫，14日齡以同等劑量進行第二次免疫，21日齡以8×10^4箇／羽的同源母株進行攻蟲，28日齡結束試驗，以存活率、增重、腸道病變記分、血便數量、卵囊減少率為觀測指標。對免疫保護效果較好的3箇免疫劑量進行重複試驗，同時設置商品化毬蟲疫苗對照組，免疫方法、試驗週期、試驗指標同第一批試驗。結果顯示：攻蟲後，不免疫攻蟲組齣現5％死亡，而各免疫組來齣現死亡；各免疫組卵囊減少率在61．57％～69．52％；200～2000免疫組的增重與不免疫不攻蟲組差異不具備顯著統計學意義（P〉0．05）；600～2000免疫組的腸道病變記分和血便數量均明顯少于不免疫攻蟲組（P〈0．05）。用600、800和1000進行重複試驗，三箇免疫組攻蟲期間均來齣現死亡，而不免疫組和疫苗對照組均齣現5％死亡；三箇免疫組的增重均明顯高于不免疫攻蟲組和疫苗對照組（P〈0．05）；早熟株免疫組的腸道病變記分和血便數量明顯低于不免疫攻蟲組（P〈0．05），而疫苗對照組與不免疫攻蟲組的相噹（P〉0．05）；卵囊減少率在66.30％-78．75％，高于疫苗對照組的51．82％。結果錶明，該柔嫩艾美耳毬蟲早熟株保持瞭良好的免疫原性，不同免疫劑量均能誘髮鷄產生免疫保護力，其中600、800和1000箇／羽的免疫效果均優于疫苗對照組，可攷慮以600箇／羽作為該早熟株在疫苗製備中的推薦免疫劑量。
위료학정유눈애미이구충（Eimenatenella）조숙주합괄적면역제량，본문설립7개조숙주면역공충조、1개불면역공충조화1개불면역불공충조，면역조적면역제량위포자화란낭100、200、400、600、800、1000화2000개／우，경소낭감염，7일령수차면역，14일령이동등제량진행제이차면역，21일령이8×10^4개／우적동원모주진행공충，28일령결속시험，이존활솔、증중、장도병변기분、혈편수량、란낭감소솔위관측지표。대면역보호효과교호적3개면역제량진행중복시험，동시설치상품화구충역묘대조조，면역방법、시험주기、시험지표동제일비시험。결과현시：공충후，불면역공충조출현5％사망，이각면역조래출현사망；각면역조란낭감소솔재61．57％～69．52％；200～2000면역조적증중여불면역불공충조차이불구비현저통계학의의（P〉0．05）；600～2000면역조적장도병변기분화혈편수량균명현소우불면역공충조（P〈0．05）。용600、800화1000진행중복시험，삼개면역조공충기간균래출현사망，이불면역조화역묘대조조균출현5％사망；삼개면역조적증중균명현고우불면역공충조화역묘대조조（P〈0．05）；조숙주면역조적장도병변기분화혈편수량명현저우불면역공충조（P〈0．05），이역묘대조조여불면역공충조적상당（P〉0．05）；란낭감소솔재66.30％-78．75％，고우역묘대조조적51．82％。결과표명，해유눈애미이구충조숙주보지료량호적면역원성，불동면역제량균능유발계산생면역보호력，기중600、800화1000개／우적면역효과균우우역묘대조조，가고필이600개／우작위해조숙주재역묘제비중적추천면역제량。
In the present study, a precocious line of Eimeria tenella was evaluated for its efficacy to protect chickens from virulent challenge. The first trial included 7 immunization-challenge groups, one nonimmunization-challenge group and one nonimmunization- nonchallenge group. Immunization doses at 100, 200, 400, 600, 800, 1000 and 2000 sporulated oocysts of the precocious line were orally administered twice to chickens at 7 and 14 days old. Chickens were challenged at 21 days old with 8× 10^4 sporulated oocysts of the parent strain and terminated at 28 days old. Survival rates, weight gains, intestinal lesion scores, fecal scores and oocyst inhibitionratios were recorded. No death occurred in all immunization-challenge groups while chickens in nonimmunization-challenge group showed 5% mortality. The reduction of oocyst ratios in immunization-challenge groups ranged from 61.57% to 69.52%. The weight gains of immunization-challenge groups with 200-2000 sporulated oocysts were similar to that of nonimmunization-nonchallenge (P〉0.05). The intestinal lesion and fecal scores of immunization-challenge groups with 600-2000 sporulated oocysts were significantly lower than that of nonimmunization-challenge group (P 〈 0.05). Subsequently, three immunization doses at 600, 800 and 1000 sporulated oocysts were repeated following the same protocol used in the first trial and a commercial coccidiosis vaccine was also included. All chickens in immunization-challenge groups were healthy but chickens in nonimmunization-challenge group and vaccine group showed 5% mortality. The weight gains of three immunization-challenge groups were significantly higher than those of nonimmunization-challenge and vaccine groups (P 〈 0.05). The intestinal lesion and fecal scores of three immunization-challenge groups were significantly lower than that of nonimmunization-challenge group (P 〈 0.05), but the difference was not significant (P〉 0.05) with vaccine group. The reduction of oocyst ratios (66.30%-78.75%) of three immunization-challenge groups was higher than that of vaccine group (51.82%). Results demonstrated that the precocious line orE. tenella maintained good immunogenicity and induced sufficient protection at doses of 600, 800 and 1000 sporulated oocysts. Therefore, the immunization dose at 600 sporulated ooeysts was recommended for use in the development of an attenuated live coccidiosis vaccine.
